During its annual Supply Chain Conference, the DEA announced that it is “in the process of modifying its regulations” on cannabis constituents. In addition to discussing fentanyl and new synthetic opioids, the DEA addressed “synthetic cannabinoids”, which the DEA contends includes delta-8 THC derived from CBD in addition to “Spice” and “Bath Salts”.